A Study Evaluating Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Overview

About this study

The purpose of this study is to evaluate efruxifermin (EFX) in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Males and non-pregnant, non-lactating females between 18 - 80 years of age inclusive, based on the date of the screening visit.
  • Previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes.
  • Cohort 1: Biopsy-proven NASH/MASH. Must have had a liver biopsy obtained ≤ 180 days prior to screening with fibrosis stage 2 or 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:
    • Steatosis (scored 0 to 3),
    • Ballooning degeneration (scored 0 to 2), and
    • Lobular inflammation (scored 0 to 3).

Exclusion Criteria:

  •  Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results.
  •  Presence of cirrhosis on liver biopsy (fibrosis stage 4).
  •  Type 1 or uncontrolled Type 2 diabetes. 

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/27/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Manal Abdelmalek, M.D.

Open for enrollment

Contact information:

Eliabe Abreu

(507) 284-0620

Abreu.Eliabe@mayo.edu

More information

Publications

Publications are currently not available